Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

OBJECTIVE: Few studies have focused on investigating resistance mechanisms in myeloma immunotherapy. This study aimed to explore the relevant factor involved in the resistance of Elotuzumab and lenalidomide. METHODS: Cell models which are resistant to Elotuzumab and lenalidomide were constructed; di...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huihan, Shi, Hua, He, Xiaowei, Liao, Aijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071208/
https://www.ncbi.nlm.nih.gov/pubmed/33907421
http://dx.doi.org/10.2147/OTT.S300328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071208/
https://www.ncbi.nlm.nih.gov/pubmed/33907421
http://dx.doi.org/10.2147/OTT.S300328

Ejemplares similares